Analyst Price Target is $18.00
▲ +57.21% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Electromed in the last 3 months. The average price target is $18.00, with a high forecast of $21.00 and a low forecast of $15.00. The average price target represents a 57.21% upside from the last price of $11.45.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Electromed.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of all ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was founded in 1992 and is headquartered in New Prague, Minnesota.